Antibody-mediated Rejection Clinical Trial
Official title:
Comparison Between Rituximab + PLX + IVIG With and Without Bortezomib in the Treatment of Antibody Mediated Kidney Transplanted Rejection
Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on the aim of reducing or eliminating DSA, some proposed different therapeutic regimens for cAMR treatment. All of these protocols were derived from previous experience using acute antibody-mediated rejection and desensitization protocols, and mainly consisted of steroids, plasma exchange (PE), IVIG and RTX in various modalities. More recently, bortezomib was also proposed.To evaluate the role of a therapeutic regimen with plasma exchange, intravenous immunoglobulins and rituximab with or without Bortezomib in chronic-active antibody-mediated rejection (cAMR) settings this study designed.
20 kidney transplant recipients (KTRs) with a diagnosis of cAMR in a prospective randomized clinical trial will be recruited in two arms : ten KTRs treated with plasmapheresis, intravenous immunoglobulins and rituximab (PE-IVIG-RTX group) vs 10 patients receiving the same therapy plus Bortezomib. Differences between transplanted kidney survival and functional outcomes 6 mo after diagnosis and histological features and donor-specific antibody (DSA) characteristics (MFI ) will be investigated between two arms. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02533596 -
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
|
N/A | |
| Completed |
NCT04367610 -
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
|
||
| Completed |
NCT05021484 -
Felzartamab in Late Antibody-Mediated Rejection
|
Phase 2 | |
| Terminated |
NCT02120482 -
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
|
N/A | |
| Terminated |
NCT03744910 -
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
|
Phase 3 | |
| Terminated |
NCT03221842 -
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
|
Phase 3 | |
| Terminated |
NCT01895127 -
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
|
Phase 2 | |
| Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
| Recruiting |
NCT05913596 -
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
|
N/A | |
| Active, not recruiting |
NCT04541914 -
Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT
|
N/A | |
| Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
| Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A | |
| Active, not recruiting |
NCT04897438 -
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
|
N/A | |
| Recruiting |
NCT05004493 -
Biorepository and Registry for Plasma Exchange Patients
|
||
| Completed |
NCT04026087 -
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
|
||
| Active, not recruiting |
NCT03994783 -
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
|
Phase 3 | |
| Not yet recruiting |
NCT05862766 -
Isatuximab in Lung Transplant Recipients
|
Early Phase 1 | |
| Recruiting |
NCT04368962 -
DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
|
||
| Completed |
NCT03444103 -
A Pilot Trial of Clazakizumab in Late ABMR
|
Phase 2 | |
| Recruiting |
NCT05140018 -
Incidence, Course and Outcome of ABMR in Kidney Transplantation
|